Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)Adi Diab, Daniel C. Cho, Nizar M. Tannir et al.|Cancer Discovery|2020Cited by 239
A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid TumorsSalah-Eddine Bentebibel, Adi Diab, Michael E. Hurwitz et al.|Cancer Discovery|2019Cited by 233
Engineering IL-2 to Give New Life to T Cell ImmunotherapyWillem W. Overwijk, Jonathan Zalevsky, Mary Tagliaferri|Annual Review of Medicine|2020Cited by 142
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic MelanomaAdi Diab, Michael E. Hurwitz, Scott S. Tykodi et al.|Journal of Clinical Oncology|2021Cited by 81
The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trialsJonathan I. Silverberg, Jonathan Zalevsky, Carsten Schmitz et al.|Nature Communications|2024Cited by 37